Pharmacokinetics of Procaterol in Elite Athletes

Procaterol in Elite Athletes - a PK Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05749536

Acronym

Procat

Enrollment

Registered

2023-03-01

Start date

2011-08-31

Completion date

2013-10-31

Last updated

2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

elite athletes

Brief summary

The purpose of the study is to find blood and urine concentrations of procaterol administrated either by inhalation or by tablets in asthmatic and non-asthmatics males. We hypotheis that the concentrations of procaterol in the blood and serum is higher after tablet intake versus inhalation.

Detailed description

Doping study

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

MALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Doctor diagnosed asthma for the asthmatic group * GINA 1-3 for the asthmatic group * Use of beta2-agonist for at least 12 months for the asthmatic group * age 18-45 * males * informed consent

Exclusion criteria

* smoker or former smoker * airway infection to weeks prior to the study or during the study * other chronic diseaes than asthma and allergy * Use of beta2-agonist 6 days prior to the study * Allergy to the study medicine

Design outcomes

Primary

Measure	Time frame	Description
urine concentration of drug 0-24 h	7 days	In healthy subjects to investigate drug farmakokenetic
serum concentration of drug 0-24 h	7 days	In healthy subjects to investigate drug farmakokenetic

Countries

Denmark

Outcome results